This episode features Dr. Richard Larson discussing the long-term outcomes of imatinib treatment for chronic myeloid leukemia, and Dr. Francisco Gonzalez-Scarano discussing the use of ocrelizumab for treatment of primary progressive multiple sclerosis. Dr. Jennifer Mitty hosts.

Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis

UpToDate® is the premier evidence-based clinical decision support resource, trusted worldwide by healthcare practitioners to help them make the right decisions at the point of care. It is proven to change the way clinicians practice medicine, and is the only resource of its kind associated with improved outcomes.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View UpToDate’s conflict of interest policy:  http://www.uptodate.com/home/conflict-interest-policy.

Please note that we are no longer producing new clinical podcasts.

Science

UpToDate® is the premier evidence-based clinical decision support resource, trusted worldwide by healthcare practitioners to help them make the right decisions at the point of care. It is proven to change the way clinicians practice medicine, and is the only resource of its kind associated with improved outcomes. Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View UpToDate’s conflict of interest policy: http://www.uptodate.com/home/conflict-interest-policy. Please note that we are no longer producing new clinical podcasts.

Share Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis

Sign up to save your podcasts

Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis

Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis

More shows like UpToDate Talk

NEJM This Week

The Curbsiders Internal Medicine Podcast